Core Insights - The company reported a significant revenue increase of 27.1% year-on-year, reaching 153 million RMB in the first half of 2025, which is a notable improvement compared to the 9.6% growth in the same period of 2024 [1][3] - The gross margin improved from 43.9% in 2024 to 47% in 2025, indicating enhanced profitability [1][3] - The net loss decreased by 31.8% to 40.9 million RMB, while the adjusted net loss was reduced by 34.4% to 22.9 million RMB [1][3] Revenue Breakdown - Domestic revenue saw a substantial increase of 56.7%, highlighting strong performance in the local market [1][3] - The six-axis product revenue accounted for 61% of total revenue, indicating a strong market position in this segment [1][3] Technological Advancements - The company has made breakthroughs in product and technology innovation, becoming the first globally to launch a comprehensive embodied robot platform that includes "robotic arm + humanoid + multi-legged" configurations [1][3] - The company operates in various sectors, including industrial manufacturing, commercial retail, medical surgery, health therapy, and scientific education, with applications in over 100 countries and regions [1][3]